Ron Rothman

Ron leads Strategic Bio Insights, a consultancy providing actionable recommendations through competitive intelligence and market intelligence on medical devices, pipeline therapeutics, nanotechnology, devices and biotechnology since 2007.  Among his other major engagements is his role as a QED Business Advisor, University City Science Center, successfully securing milestone-based funding of four medical device ventures for market-driven prototype development and pre-clinical proof-of-concept studies; Member, Board of Directors, Pharmaceutical Consulting Consortium, Inc., a 501(c)(6) nonprofit association with 400 Life Science industry members; and whose mission is to help early- to mid-stage life science companies to succeed by improving their business model, strategies and commercial viability.

Ron is also the Chief Business Officer and Founder, BioRegenics, Inc., an orthopedic medical device development company focused on innovation for repairing cartilage and bone.

• Biopharma: Diagnostics, Drug Delivery, Therapeutics 
• Therapeutics: Dermatology, Immunology, Autoimmune & Inflammation, Infectious Diseases, Musculoskeletal Disorders, Orthopedics - bone, Neurodegenerative, Oncology, Ophthalmology, Regenerative Medicine - Tissue Engineering, Respiratory & Pulmonary, Transplantation 
• Biomedical-Other: Precision Health 
• Digital Health/Health IT 
• Other: Go-to-market strategy, Ideation, Competitive Intelligence, Regulatory, Lean Start-up Business model